Coherus BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.1 Mil. Coherus BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $478.7 Mil. Coherus BioSciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-193.4 Mil.
Coherus BioSciences's debt to equity for the quarter that ended in Dec. 2023 was -2.49.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Coherus BioSciences's Debt-to-Equity or its related term are showing as below:
CHRS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.5 Med: 1.64 Max: 4.88
Current: -2.49
During the past 12 years, the highest Debt-to-Equity Ratio of Coherus BioSciences was 4.88. The lowest was -3.50. And the median was 1.64.
Coherus BioSciences Debt-to-Equity Historical Data
The historical data trend for Coherus BioSciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Coherus BioSciences Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
1.79 |
1.48 |
4.29 |
-3.50 |
-2.49 |
|
Coherus BioSciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-3.50 |
-2.44 |
-2.74 |
-3.58 |
-2.49 |
Competitive Comparison
For the Biotechnology subindustry, Coherus BioSciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus BioSciences Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's Debt-to-Equity falls into.
Coherus BioSciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Coherus BioSciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Coherus BioSciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus BioSciences (Coherus BioSciences) Business Description
Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
| Dennis M Lanfear |
director, officer: President and CEO |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Michael Lee Ryan |
director |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Mcdavid Stilwell |
officer: Chief Financial Officer |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Bryan J Mcmichael |
officer: See Remarks |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065 |
| Paul Reider |
officer: Chief Commercial Officer |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Jill O'donnell-tormey |
director |
C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Charles W. Newton |
director |
46 FREDRICK AVENUE, ATHERTON CA 94027 |
| Lee Nisley Newcomer |
director |
264 BUSHAWAY ROAD, WAYZATA MN 55391-1901 |
| James Healy |
director |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Vladimir Vexler |
officer: Chief Scientific Officer |
333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Vincent R Anicetti |
officer: Chief, Quality & Compliance |
COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
| Jean-frederic Viret |
officer: Chief Financial Officer |
ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Mark Stolper |
director |
150 COTNER AVENUE, LOS ANGELES CA 90025 |
| Alan C Mendelson |
director |
ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025 |
| Kimberly Jo Tzoumakas |
director |
1170 FAIRFAX STREET, BIRMINGHAM MI 48009 |
Coherus BioSciences (Coherus BioSciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your